Introduction
Circadian rhythms in mammals are generated and maintained by a neural clock located within the suprachiasmatic nucleus (SCN) (Rusak and Zucker, 1979; Moore, 1983; Klein et al., 1991) . Clock time is synchronized to the light/dark cycle by photic information relayed from the retina to the SCN via the retinohypothalamic tract (Hendrickson et al., 1972; Moore and Lenn, 1972; Pickard, 1982; Youngstrom and Nunez, 1986; Johnson et al., 1988) and by an indirect projection from the intergeniculate leaflet (IGL) (Card and Moore, 1982; Johnson et al., 1989) . Projections from the IGL and the midbrain raphe nuclei also convey nonphotic input to the SCN via neuropeptide Y-containing and serotonin (5-HT)-containing projections, respectively (Albers and Ferris, 1984; Biello et al., 1994; Meyer-Bernstein and Morin, 1996; Marchant et al., 1997) .
Despite the extensive literature on the action of 5-HT in the SCN, its physiological roles, particularly those related to behavioral phase regulation, remain speculative. For example, there is evidence that 5-HT acts in the SCN to mediate the clock-resetting effects of behavioral stimulation. This includes findings that 5-HT agonists applied to the SCN in vitro or in vivo reset circadian phase (Prosser et al., 1990 Medanic and Gillette, 1992; Challet et al., 1998; Ehlen et al., 2001 ) and that behavioral phaseresetting manipulations evoke SCN 5-HT release (Dudley et al., 1998; Grossman et al., 2000) . Conversely, reports that raphe lesions (Meyer-Bernstein and Morin, 1998) , treatment with 5-HT antagonists (Antle et al., 1998) , or depletion of 5-HT in the SCN (Bobrzynska et al., 1996) do not block behavioral phase shifting argue against a role of 5-HT in circadian clock resetting.
Critical questions also remain regarding the respective roles of the dorsal raphe nucleus (DRN) and the median raphe nucleus (MRN) in regulating SCN serotonergic activity. Mapping studies reveal that the MRN is the sole source of SCN serotonergic innervation (Vertes and Kocsis, 1994; Moga and Moore, 1997) . Nevertheless, stimulation of the DRN produces 5-HT-related effects in the SCN, including inhibition of light-induced Fos expression (Meyer-Bernstein and and neuronal discharge (Yu et al., 1997) , attenuation of light-induced phase shifts (Weber et al., 1998) , and 5-HT release (Dudley et al., 1999) . These findings, together with the raphe-SCN mapping results, suggest that the DRN communicates with the SCN via a multisynaptic interaction through the MRN. This hypothesis is supported by reports that the MRN and DRN are functionally connected (Mokler et al., 2001 ; Morin and Pace, 2001 ) and that DRN-electrically stimulated, but not MRNelectrically stimulated, SCN 5-HT release is blocked by 5-HT antagonists, indicative of a multisynaptic DRN3 MRN3 SCN pathway . The present experiments were undertaken to characterize this pathway using targeted intra-raphe injections of 5-HT antagonists with electrical and behavioral stimulations. This approach was also used to test the hypothesis that this pathway modulates behavioral phase-resetting responses. Because intra-raphe GABAergic transmission is important for regulating serotonergic activity (Gervasoni et al., 2000) , its role in controlling SCN 5-HT release and nonphotic phase resetting was also a major focus of this study.
Materials and Methods

Animals
Adult male Syrian hamsters (Mesocricetus auratus), raised from breeder pairs obtained from Harlan Sprague Dawley (Indianapolis, IN), were used in these studies. These animals were group housed (two to three per cage) in a climate-controlled (20 -22°C) vivarium under a 14 hr light/10 hr dark photo period (LD) (200 -250 lux) . Preceding experimentation, animals were individually housed in a circular polycarbonate cage to facilitate microdialysis and brain stimulation procedures. Rodent chow (Prolab 3000; PMI Feeds, St. Louis, MO) and water were provided ad libitum.
Electrical and pharmacological stimulations of the raphe
Animals received intracranial implants (DRN-stimulating or MRNstimulating electrode, DRN or MRN microinjection cannula, and SCN microdialysis probe) using stereotaxic surgical procedures (head level in a stereotaxic frame) with sodium pentobarbital (Nembutal; 50 mg/kg) as anesthetic. A bipolar-stimulating electrode (Plastics One, Roanoke, VA) was aimed at the DRN [anteroposterior (AP) ϭ Ϫ4.7 mm from bregma; lateral (L) ϭ ϩ1.7 mm from midline; horizontal (H) ϭ Ϫ4.8 mm from dura at a 20
o angle] or MRN (AP ϭ Ϫ4.4 mm from bregma; L ϭ Ϫ2.3 mm from midline; H ϭ Ϫ6.8 mm from dura at a 20 o angle), and a unilateral 24 gauge stainless steel guide cannula (Plastics One) was implanted contralaterally with its tip situated 1 mm above the DRN (AP ϭ Ϫ4.7 mm from bregma; L ϭ Ϫ1.7 mm from midline; H ϭ Ϫ3.8 mm from dura at a 20 o angle) or MRN (AP ϭ Ϫ4.4 mm from bregma; L ϭ Ϫ2.3 mm from midline; H ϭ Ϫ5.8 mm from dura at a 20°angle). A microdialysis probe was targeted at the lateral margin of the SCN (AP ϭ 0.3 mm from bregma; L ϭ ϩ0.3 mm from midline; H ϭ Ϫ8.0 mm from dura). The implants were secured to the skull by three stainless steel screws and dental acrylic. Experiments were initiated 24 hr after surgery.
For DRN stimulation, constant current (20 min duration at 150 or 500 A, 10 Hz stimulus frequency, and 2.0 msec pulse duration) was delivered to a bipolar electrode from a stimulus isolator (World Precision Instruments, Sarasota, FL) coupled to a Grass S11 stimulator (Grass Instruments, Quincy, MA). Drug injections into the DRN or MRN were undertaken by inserting a 31 gauge injection needle connected by polyethylene tubing to a 10 l Hamilton syringe into the guide cannula with its tip extending 1.0 mm beyond the end of the cannula. A 31 gauge stylet inserted into the guide cannula was used to maintain patency between injections. Details of microdialysis probe methodology are provided below.
Microdialysis-HPLC
Procedures for microdialysis probe construction are similar to those of previous studies (Dudley et al., 1998) . Concentrically designed probes were constructed from a 26 gauge stainless steel outer cannula (Small Parts, Miami, FL) into which was inserted a beveled 32 gauge fused silica tube (Polymicro Technologies, Phoenix, AZ). Hemicellulose dialysis tubing [molecular weight of 12 kDa cutoff; 230 m outer diameter; Spectra-por (Fisher Scientific, Pittsburgh, PA)] was inserted ϳ1.0 mm into the outer cannula and secured with epoxy glue. The distal end of the membrane was cut to a length of 1.5 mm, and the tip was sealed with epoxy, providing an active dialyzing length of 1.0 mm. Microdialysis was performed by continuously perfusing probes with filtered artificial CSF (ACSF) composed of the following (in mM): 147 NaCl, 4.0 KCl, 1.8 CaCl 2 , pH 7.5, at a flow rate of 1.2 l/min using a calibrated syringe pump (CMA/100; Bioanalytical Systems, West Lafayette, IN) attached to an overhead liquid swivel (Instech, Plymouth Meeting, PA). The assembly allowed the animals freedom of movement within the cage throughout the duration of the experiment. For all experiments, measurement of extracellular 5-HT in the SCN was aided by adding 4.0 M citalopram to the perfusate. The sampling interval was 20 min.
Microdialysate was analyzed for 5-HT using HPLC (Bioanalytical Systems) with amperometric electrochemical detection. Samples were injected onto a 100 ϫ 1 mm 3 C-18 reverse-phase microbore column. The mobile phase consisted of 9.45 gm of monochloroacetic acid (Fisher Scientific), 0.2 gm of octanesulfonic acid, and 0.25 gm of Na 2 EDTA (Eastman Kodak, Rochester, NY) dissolved in 1.0 l HPLC-grade distilled water, pH 3.1. Tetrahydrofuran (6.0 ml) was added after filtration. Flow rate of the mobile phase through the column was 90 l/min. A 3.0 mm glassy carbon radial-flow electrochemical detector set at a potential of 590 mV relative to an AgCl reference electrode was used to measure 5-HT. The lower level of sensitivity (signal Ն5ϫ background) was ϳ500 fg. Electrode output was interfaced with an IBM-compatible computer that recorded and analyzed the data. Authenticity of the 5-HT peak in SCN microdialysate was verified by predictable changes in its size after electrical and pharmacological stimulations of the raphe and localized administration of pharmacological agents to the SCN via the dialysis probe (Dudley et al., 1998) .
Circadian wheel-running activity measurements
Daily wheel-running activity was recorded by a magnetic switch attached to a running wheel (14 inch diameter, 1.5 kg; zcomNalge Nunc International, Rochester, NY) with its output interfaced with a computerized data acquisition system (Dataquest, Sunriver, OR). Circadian phase resetting was assessed using a modified Aschoff type II procedure (Aschoff, 1965) , in which animals maintained under LD up to the time of experimentation were released into total darkness (DD) at the beginning of the experimental treatments initiated at zeitgeber time (ZT) 6. Phase shifts of the circadian wheel-running rhythm were calculated as the difference between the averaged activity onset for 5 d preceding drug treatment and onsets predicted by least squares regression analysis of activity onsets from days 3-10 after treatment. Activity onset was defined as the first 10 min period in which the total number of wheel revolutions (revs) exceeded 50% of the maximum number of revolutions per 10 min measured that day and was followed by at least 1 hr of sustained activity.
Experimental protocols
Effects of 5-HT antagonists on DRN-electrically stimulated SCN 5-HT release. A 20 min period of DRN electrical stimulation was begun in the middle of the light phase at ZT 6 (ZT 12 was time of lights off). Microinjections of drugs [the 5-HT 1,2,7 antagonist metergoline (2 g, 1 l volume; Sigma, St. Louis MO); the selective 5-HT 7 antagonist DR4004 (Kikuchi et al., 1999 ) (2 g, 1 l volume; Meiji Seika Kaisha, Yokohama, Japan)] or vehicle (1:1 ACSF/DMSO, 1 l volume) were administered via an injection cannula aimed at the DRN or MRN 20 min before the onset of the DRN stimulation. For SCN measurements, the microdialysis probe was perfused for a 2 hr equilibration period beginning at ZT 3, followed by a 1 hr sample collection period to establish baseline 5-HT release levels. Microdialysis sampling was continued for 2 hr after the antagonist injection. Trials were conducted over 3 consecutive days on the same animal, with drugs or injection vehicle administered randomly. Control experiments assessing the effects of intra-raphe administration of metergoline, DR4004, or vehicle alone (without electrical stimulation) on SCN 5-HT release were also undertaken.
Effects of intra-DRN 5-HT antagonists on sleep deprivation-induced SCN 5-HT release.
The procedures used for sleep deprivation were similar to those used in a previous study (Grossman et al., 2000) . Beginning at ZT 6, animals outfitted with a microdialysis probe in the SCN and an injection reentry cannula aimed at the DRN were aroused and maintained in the waking state in their home cage for 3 hr by continuous gentle handling and light puffs of air. After the 3 hr experimental period, the animals were left undisturbed. These procedures were performed under dim red light (Ͻ1.0 lux) because bright light inhibits nonphotic phase resetting . Microdialysis sampling was undertaken continuously from ZT 5 to 10 with a 20 min sampling
interval. An initial intra-DRN metergoline [(experimental) 2 g, 1 l volume)] or vehicle [(control) 1:1 DMSO/ACSF, 1 l volume] microinjection was administered 20 min before the onset of the sleep deprivation, and a second microinjection of the same respective solution was delivered 2 hr later. The experiment was undertaken using a paired design in which the animals received both experimental and control treatments in random order over 2 consecutive days.
Intra-DRN and intra-MRN GABAergic effects on SCN 5-HT release. Microinjections of the GABA A antagonist bicuculline (125 ng, 500 nl volume) or the GABA A agonist muscimol (25 ng, 500 nl volume; Sigma) were administered to the DRN and the MRN to explore the role of raphe GABAergic mechanisms in regulating SCN 5-HT release. All drugs were administered by microinjection aimed at the DRN or MRN at ZT 6. Microdialysis measurements of SCN 5-HT release were undertaken as described above. Sampling was undertaken continuously for 3 hr (1 hr before and 2 hr after drug injection).
Intra-DRN 5-HT 7 and GABA A antagonist effects on SCN 5-HT release. Coapplications of bicuculline and DR4004 in the DRN were undertaken to determine whether stimulation of SCN 5-HT release elicited by GABA A receptor antagonism is prevented by 5-HT 7 receptor blockade in the same manner as DRN-electrically stimulated SCN 5-HT release is blocked with 5-HT antagonists. Animals received microinjection of DR4004 (2 g, 1 l volume) 20 min before microinjection of bicuculline (125 ng, 500 nl volume) delivered from the same cannula at ZT 6. Microdialysis measurements of SCN 5-HT release were undertaken continuously for 3 hr (1 hr before and 2 hr after bicuculline injection).
Intra-DRN 5-HT 7 antagonist and GABA A agonist effects on novel wheelinduced phase resetting. Intra-DRN injections of DR4004 and muscimol were undertaken to determine whether the pharmacological interventions that suppressed SCN 5-HT release could also inhibit behavioral phase resetting. Novel wheel access was used rather than sleep deprivation in these trials because the former stimulus, due to the inter-animal variation in wheel-running performance, offers the advantage of testing drug effects over a broader range of phase-resetting response. A possible potentiating effect of bicuculline on phase resetting was not evaluated because of the acute arousal reaction induced by intra-DRN injection of this drug. The circadian wheel-running activity rhythm of hamsters outfitted with a unilateral reentry injection cannula aimed at the DRN was measured for a minimum of 10 d under LD preceding experimentation. On the day of treatment, the animals received an injection of DR4004, muscimol (same doses as those used in the 5-HT release experiments), or vehicle and were removed from their home cage and confined in a novel wheel for a 3 hr period beginning at ZT 6. A second injection of respective drug or vehicle was administered at ZT 7.5, and the animals were returned to their home cage at ZT 9. The animals were released into DD at the beginning of the novel wheel confinement, and their phase-resetting response was determined using the modified Aschoff II procedure described above. The number of revolutions induced by the novel wheel exposure was recorded over the 3 hr experimental period and after return to the home cage and wheel.
Histological evaluations of intracranial implant sites
After completion of the experiments, the locations of the implants were verified histologically. Hamsters were deeply anesthetized with Nembutal and perfused intracardially with 100 ml of buffered 4% paraformaldehyde. The brains were removed and postfixed in 4% paraformaldehyde overnight. Cryostat sections of the SCN region (20 m) were stained with cresyl violet for light microscopic verification of microdialysis probe placement. A separate tissue block containing the midbrain was serially sectioned (60 m) on a vibratome and processed immunocytochemically for 5-HT to verify electrode or cannula tip location among 5-HT neurons of the MRN or DRN. Staining for 5-HT was undertaken using a rabbit polyclonal anti-5-HT (Eugenetech, Farmendale, NJ).
Brain implant specificity considerations
Electrical stimulations. Nonspecific excitation by passive current spread from the DRN to the MRN was evaluated previously using electrodes aimed ϳ0.8 mm dorsolateral to the MRN (Dudley et al., 1999) . Stimulation from these electrodes did not affect SCN 5-HT release; therefore, it is unlikely that passive current flow from electrodes in the DRN would affect MRN neurons located farther away (ϳ2.0 mm ventral) from the stimulation site.
Drug stimulations. Diffusion of drugs between the DRN and MRN was evaluated by comparing responses of the different nuclei with the same doses of drugs. The differential effects obtained [i.e., threefold greater response to 8-OH-DPAT or WAY 100635 injections into the MRN versus the DRN (Dudley et al., 1999) ] indicate that the effects of the drugs were registered primarily at the site of injection. Also, the lack of effect of DRN injections that were off target by ϳ1 mm supports this contention.
5-HT microdialysis measurements. Site specificity of the SCN microdialysis measurements has been empirically evaluated (Dudley et al., 1999) . Probes with a small window of active dialysis membrane were aimed medially at the SCN to limit sample contamination from 5-HT of extra-SCN origin. This method provided equivalent estimations of peak DRN-stimulated 5-HT release as obtained using the conventional concentric probes, confirming that most of the of 5-HT measured by these probes is from SCN origin.
Statistics
The SCN 5-HT release data were normalized as a percentage of the pretreatment baseline level. Pretreatment versus post-treatment comparisons were undertaken using one-way repeated measures ANOVA followed by the Student-Newman-Keuls test. Treatment versus control comparisons for a given time point were analyzed using a paired t test. A two-way ANOVA was also undertaken to compare treatment and site effects over time. Drug effects on wheel-running-induced phase resetting were analyzed using a one-way ANOVA followed by the Student-Newman-Keuls test. For all procedures, the level of significance was set at p Ͻ 0.05.
Results
Intra-raphe 5-HT antagonist injection inhibits 5-HT release in the SCN DRN 5-HT antagonist treatments
Pretreatment with an intra-DRN injection of metergoline abolished the DRN-electrically stimulated release of 5-HT in the SCN [peak levels within 40 min after stimulation were 176 Ϯ 17 vs 96 Ϯ 10% of baseline for vehicle and metergoline treatments, respectively (n ϭ 6 per group; p Ͻ 0.01) (Fig. 1 A) ]. A two-way ANOVA revealed that drug treatment, time, and their interaction were all significant ( p Ͻ 0.01). In a similar manner, pretreatment of DRN-electrically stimulated animals with intra-DRN injection of the highly selective 5-HT 7 antagonist DR4004 blocked the stimulation of 5-HT release in the SCN [peak levels within 40 min after stimulation were 196 Ϯ 26 vs 100 Ϯ 9% of baseline for vehicle and DR4004 treatments, respectively (n ϭ 5 per group; p Ͻ 0.01) (Fig. 1 B) ]. Drug treatment, time, and their interaction were all significant ( p Ͻ 0.01). Intra-DRN injections of metergoline or DR4004 alone (without electrical stimulation) reduced basal release of 5-HT in the SCN during an equivalent sampling period by ϳ25% versus vehicle (n ϭ 4 per group; p Ͻ 0.05 for both drugs) (Fig. 1C) .
MRN 5-HT antagonist treatments
Pretreatment of DRN-electrically stimulated animals with intra-MRN injection of metergoline or DR4004 had similar effects as those described for intra-DRN antagonist applications. DRNelectrically stimulated release of 5-HT in the SCN was prevented by metergoline [peak levels within 40 min after stimulation were 187 Ϯ 17 vs 104 Ϯ 15% of baseline for vehicle and metergoline treatments, respectively (n ϭ 6 per group; p Ͻ 0.01) (Fig. 2 A) ]. Drug treatment, time, and their interaction were all significant ( p Ͻ 0.01). Similar to metergoline, DRN-stimulated SCN 5-HT release was blocked by DR4004 [peak levels within 40 min after stimulation were 168 Ϯ 20 vs 95.5 Ϯ 6% of baseline for vehicle and DR4004 treatments, respectively (n ϭ 4 per group; p Ͻ 0.05) (Fig. 2 B) ]. Drug treatment, time, and their interaction were all significant ( p Ͻ 0.01).
Intra-DRN metergoline blocks behaviorally induced 5-HT release in the SCN
Like previous reports from this laboratory (Grossman et al., 2000) , 3 hr of sleep deprivation under dim red light during the subjective midday induced a prolonged increase in 5-HT release in the SCN with maximal levels [151 Ϯ 10% of pretreatment baseline (n ϭ 5); p Ͻ 0.05] occurring within 2 hr from the onset of treatment (Fig. 3) . The average increase in 5-HT release throughout the entire 3 hr treatment period was 134 Ϯ 3% ( p Ͻ 0.05 vs baseline). In marked contrast, the stimulatory effect of sleep deprivation on SCN 5-HT release was abolished in animals treated with an intra-DRN injection of the 5-HT 1,2,7 antagonist metergoline (Fig. 3) . The average change in 5-HT release throughout this treatment period was Ϫ17 Ϯ 9% [p Ͼ 0.37 vs pretreatment baseline (n ϭ 5); p Ͻ 0.05 vs vehicle controls]. Two-way ANOVA revealed a significant difference between metergoline and vehicle treatment ( p Ͻ 0.01).
Raphe GABA receptors modulate 5-HT release in the SCN Bicuculline stimulates SCN 5-HT release Microinjection of the GABA A receptor antagonist bicuculline into the DRN dramatically stimulated 5-HT release in the SCN, with maximal levels (264 Ϯ 64% of baseline; p Ͻ 0.05; n ϭ 5) sustained over a 40 min period after injection (Fig. 4 A) . The stimulated increase of 5-HT release was approximately twice that observed in response to electrical stimulation or sleep deprivation (Fig. 4A) . Injection of bicuculline into the MRN also had a stimulatory effect on SCN 5-HT release, but this was less than induced by the DRN treatment, with maximal levels (174 Ϯ 16% of baseline; p Ͻ 0.05; n ϭ 5) occurring within 40 min after injection (Fig. 4 A) . Two-way ANOVA revealed significance between DRN and MRN groups, time, and the interaction between time and groups ( p Ͻ 0.01).
Muscimol inhibits SCN 5-HT release
Microinjection of the GABA A receptor agonist, muscimol, into the DRN reduced 5-HT release in the SCN to 72 Ϯ 8% of baseline levels within 20 min after injection ( p Ͻ 0.05; n ϭ 6) (Fig. 4 B) . Microinjection of muscimol to the MRN also reduced SCN 5-HT release (73 Ϯ 7% of baseline; n ϭ 5; p Ͻ 0.05) (Fig. 4 B) . A two-way ANOVA revealed differences between DRN and MRN groups ( p Ͻ 0.01), time ( p Ͻ 0.01), and the interaction between time and groups ( p Ͻ 0.05). However, as evident in the bicuculline response, the latency of muscimol action in the MRN was greater than that observed for the DRN, with maximal suppression occurring 60 min after injection.
Intra-DRN DR4004 inhibits bicuculline-stimulated SCN 5-HT release
Pretreatment with intra-DRN microinjection of DR4004 blocked the stimulatory effect of intra-DRN microinjection of bicuculline on SCN 5-HT release (Fig. 4C) . Two-way ANOVA revealed differences between bicuculline and DR4004 plus bicuculline treatments and time ( p Ͻ 0.01). The similarity in action between the blocking effects of intra-DRN 5-HT antagonists on GABA antagonist and electrical and behavioral stimulations of SCN 5-HT output indicates the involvement of GABA in the same pathway(s) mediating both the exogenous and endogenous DRNmediated activation of 5-HT release in the SCN.
Electrical DRN stimulation induces 5-HT release in the MRN
A direct functional serotonergic communication between the DRN and MRN is indicated by our finding that stimulation of the DRN elicits 5-HT release in the MRN. The 20 min pulse of DRN electrical stimulation increased extracellular 5-HT release in the MRN by 142 Ϯ 21% of nonstimulated control levels ( p Ͻ 0.05; n ϭ 6) (Fig. 5) .
The DRN modulates behavioral circadian phase resetting
Similar to other studies in the Syrian hamster (Bobrzynska and Mrosovsky, 1998; Meyer-Bernstein and Morin, 1998) , there was a wide range of response to novel wheel access, with the majority of animals of the vehicle control and drug treatment groups running Ͻ400 revolutions over the 3 hr treatment period (Fig. 6) . Control animals exceeding the 400 -500 revolution level exhibited peak phase-advancing responses averaging 136 Ϯ 23 min (n ϭ 4), whereas most individuals running below this level responded with considerably smaller responses averaging 44 Ϯ 10 into the DRN (n ϭ 6) and MRN (n ϭ 5) suppressed 5-HT release, with the duration of this effect being greater in the DRN. C, The stimulatory effect of intra-DRN injection of bicuculline is abolished by intra-DRN pretreatment with DR4004 (n ϭ 5 per group). For all graphs, a p Ͻ 0.05 versus pretreatment baseline levels; * p Ͻ 0.05 versus complementary site-drug treatment for a given time point. Data are mean Ϯ SEM. Differences in bicuculline potency between the two experiments were caused primarily by the greater variability in response in A and possibly differences in drug potency between different lots that were used. min (n ϭ 11; p Ͻ 0.05). Thus, under control conditions, the 400 -500 revolution range was considered to be an index for attaining maximal phase-advancing response. Animals receiving intra-DRN muscimol that ran at or above this range had phase advances that were significantly smaller than controls running in this range (46 Ϯ 22 min; n ϭ 4; p Ͻ 0.05 vs controls) (Fig. 7) . Muscimol-treated animals running below this range (n ϭ 6) also had phase advances that were less than those of controls running in a similar range (11 Ϯ 6 min; n ϭ 6; p Ͻ 0.05 vs controls). Animals receiving intra-DRN DR4004 that ran above this range had phase advances that were smaller than controls (31 Ϯ 15 min; n ϭ 3; p Ͻ 0.05 vs controls) (Fig. 7) . DR4004-treated animals running less than this range had phase advances similar to both the control and muscimol groups (26 Ϯ 5 min; n ϭ 12; both p Ͼ 0.05). Actograms representing the three treatment groups are presented in Figure 8 .
Despite the individual variability in wheel-running response, the overall average revolutions for every animal in each treatment group during the 3 hr treatment period did not differ significantly (control, 337 Ϯ 55 revs; muscimol, 386 Ϯ 71 revs; DR4004, 214 Ϯ 62 revs; both drug groups p Ͼ 0.15 vs control). However, overall analysis of phase shifting for every animal in each group revealed significant drug-related differences in response (control, 68 Ϯ 14 min; muscimol, 25 Ϯ 10 min; DR4004, 27 Ϯ 5 min; both drug groups, p Ͻ 0.05 vs control). Also, for animals running at or above the 400 -500 revolution range, the mean level of running for controls also was not statistically significant from the drug groups (control, 630 Ϯ 93; muscimol, 628 Ϯ 51; DR4004, 612 Ϯ 106; p Ͻ 0.98) (Fig. 7) . Therefore, the reduced phase-resetting response of animals treated with muscimol or DR4004 that performed at or above this range is not attributable to a drug-related suppression of wheel running.
Discussion
Serotonergic input to the SCN from the midbrain raphe nuclei is important for maintaining normal circadian rhythmicity; however, the respective roles of the DRN and MRN in regulating this input remain uncertain. The MRN is the only direct source of serotonergic innervation to the SCN in the Syrian hamster , but stimulation of either raphe nucleus in this species elicits multiple 5-HT-related effects in the SCN (Meyer-Bernstein and Morin, 1996 Yu et al., 1997; Weber et al., 1998) , including 5-HT release (Dudley et al., 1999) . We therefore proposed a multisynaptic DRN3 MRN3 SCN pathway to match these findings with the raphe-SCN mapping data. This pathway is supported by observations that DRNelectrically stimulated 5-HT release in the SCN is blocked by . Relationship between the number of wheel revolutions during the 3 hr novel wheel exposure and induced phase-advance shifts in animals that received intra-DRN injection of vehicle(VEH),muscimol(MUSC),orDR4004.Forreference,alinewasplottedforthecontroldataonly, using a sigmoidal 3 parameter equation (Sigma Plot, Jandel Scientific, Corte Madera, CA).
Figure 7.
Effects of intra-DRN muscimol and DR4004 injection on novel wheel-induced phase resetting. Top, Phase-advance shifts for animals that ran at or exceeded the 400 -500 revolution index range for maximal shifting response. Bottom, Number of wheel revolutions for groups of animals represented in the top. Vehicle, n ϭ 4; muscimol, n ϭ 4; DR4004, n ϭ 3. For each graph, bars with different letters are significantly different. Data are mean Ϯ SEM.
systemic treatment with the 5-HT 1,2,7 antagonist metergoline, indicative of a multisynaptic, 5-HT-sensitive route from the DRN to the SCN (Dudley et al., 1999; Glass et al., 2000) . The present results reveal also that the 5-HT-sensitive components of this pathway are associated with the raphe nuclei themselves because DRN-electrically stimulated SCN 5-HT release is blocked by intra-DRN and intra-MRN injections of 5-HT antagonists and DRN stimulation induces 5-HT release in the MRN. The physiological significance of these observations is underscored by the demonstration that the acute increase in SCN 5-HT release induced by sleep deprivation is similarly blocked by intra-DRN treatment with metergoline. Importantly, a modulatory role of the DRN in nonphotic phase resetting is indicated by the finding that intra-DRN injections of DR4004 or the GABA A agonist muscimol (both of which suppress SCN 5-HT release) attenuate, but do not block, circadian phase-advance shifts induced by novel wheel access.
It is notable that intra-DRN 5-HT antagonist application blocks the effects of electrical stimulation of DRN cells, suggesting that the 5-HT antagonists block postsynaptic targets of the stimulated DRN cells. The marked similarities between the inhibitory effects of intra-DRN 5-HT antagonists on behavioral, bicuculline, and electrically stimulated SCN 5-HT release indicate that the electrical stimulation activates the same population of DRN neurons as do these other modes of stimulation.
Raphe 5-HT 7 receptors regulate behavioral 5-HT release in the SCN The present observations that DRN-electrically stimulated SCN 5-HT release and novel wheel-induced phase shifts are attenuated by intra-DRN application of metergoline and/or DR4004, both of which antagonize the 5-HT 7 receptor, implicate DRN 5-HT 7 receptors in the regulation of circadian timekeeping. The 5-HT 7 receptor has been localized immunocytochemically in fibers and cell bodies in various circadian-related brain sites, including the DRN and SCN (Pickard and Belenky, 2000; Duncan et al., 2001) , and is thought to mediate the circadian phase-resetting effect of 5-HT in the SCN (Lovenberg et al., 1993; Ehlen et al., 2001) . 5-HT 7 receptor binding has been identified autoradiographically in the DRN, MRN, IGL, and SCN of hamsters, and significantly, only 5-HT 7 receptor binding in the DRN changes with aging and in accordance with age-related 8-OH-DPAT phase-resetting effects (Duncan et al., 1999) . This points to a unique role of DRN 5-HT 7 receptors in regulating serotonergic circadian clockresetting responses, which has direct relevance to the present data linking these DRN receptors to circadian phase-regulating mechanisms.
Serotonergic regulation of circadian phase
An important issue related to the present assessment of raphe function is that of a direct phase-regulating action of 5-HT in the SCN (for review, see Morin, 1999; Mistlberger et al., 2000) . The intrinsic pattern of activity of 5-HT neurons varies in accordance with behavioral state (Trulson and Jacobs, 1983; Jacobs and Fornal, 1997) , and 5-HT release induced in the SCN by behavioral phase-resetting stimuli (Dudley et al., 1998; Grossman et al., 2000) could serve as an intrinsic clock-resetting feedback signal. Although a role for 5-HT is not certain (Bobrzynska et al., 1996; Mintz et al., 1997; Meyer-Bernstein and Morin, 1998) , evidence supporting a phase-resetting action of 5-HT in the SCN includes reports that in vitro application of 5-HT receptor agonists to the SCN brain slice preparation during subjective midday advances the circadian rhythm of neuronal activity (Prosser et al., 1990 Medanic and Gillette, 1992; Shibata et al., 1992) . Also, in vivo administration of 8-OH-DPAT into the third ventricle upstream from the SCN in rats (Edgar et al., 1993) or bilateral microinjections of 8-OH-DPAT into the SCN region of hamsters (Challet et al., 1998) phase advances the circadian clock, and depletion of 5-HT in the SCN by neurotoxic lesioning prevents entrainment to daily schedules of activity in mice (Edgar et al., 1997; Marchant et al., 1997) . More recently, perfusions of the SCN with 8-OH-DPAT or 5-HT using reverse microdialysis in hamsters were shown to phase advance the clock at midday in a tetrodotoxin-insensitive manner, suggesting a direct in vivo phase-resetting action of 5-HT on clock cells (Ehlen et al., 2001 ).
Intra-raphe GABAergic mechanisms regulate SCN 5-HT release
The respective stimulatory and inhibitory effects of intra-raphe injection of the GABA A antagonist bicuculline and the GABA A agonist muscimol on SCN 5-HT release support a role of GABA in the regulation of midbrain raphe activity. These results are consistent with reports that GABA inhibits DRN neuronal activity (Gallager and Aghajanian, 1976; Levine and Jacobs, 1992) and mediates IPSPs in DRN serotonergic cells (Pan and Williams, 1989) . Also, reduced DRN neuronal discharge during sleep is associated with increased GABA release, and this reduction is reversed by bicuculline (Levine and Jacobs, 1992; Nitz and Siegel, 1997; Gervasoni et al., 2000) . The suspected regulatory actions of raphe GABAergic transmission in SCN 5-HT release and the timing of the sleep-wake cycle have important implications for circadian phase regulation. Notably, behavior-related changes in raphe GABAergic activity could underlie the circadian phaseresetting effects of sleep deprivation . During the day, when SCN 5-HT release is low (Dudley et al., 1998) , there is strong GABAergic inhibition of raphe activity associated with the sleep state (discussed above). In the proposed model in Figure 9 , sleep deprivation-induced SCN 5-HT release (Grossman et al., 2000) is attributed to a behavior-arousalmediated suppression of DRN GABAergic tone. The potentiated 5-HT output may in turn mediate behaviorally induced phase resetting. This model is supported by the present findings that (1) 5-HT release at midday is stimulated by bicuculline, and (2) this release is blocked by intra-DRN injection of metergoline, as is sleep deprivation-induced SCN 5-HT release. It is possible that the circadian phase-related actions of intra-DRN GABA involve the same GABA A -benzodiazepine receptor population responsible for mediating the phase-resetting effects of triazolam (Turek and Losee-Olson, 1986; Turek and Van Reeth, 1988; Van Reeth and Turek, 1989; Marchant and Morin, 1999) . However, it is unlikely that the DRN is a target for the phase-shifting action of triazolam (Meyer-Bernstein and Morin, 1998; Marchant and Morin, 1999) , and triazolam and behavioral stimuli do not act via the same phase-resetting mechanism (Meyer-Bernstein and Morin, 1998; Janik and Mrosovsky, 1992; Marchant and Morin, 1999) .
DRN modulation of behavioral phase resetting
Intra-DRN treatments with DR4004 or muscimol at dosages that suppress DRN signaling to the SCN significantly attenuated the phase-advancing effect of novel wheel access. Notably, the mean shifting response of the drug-treated animals running at or more than the 400 -500 revolution range was only ϳ30% of maximally shifting vehicle controls running with similar exertion. It is therefore apparent that inhibiting DRN output can attenuate behavioral phase shifting, which is not caused by drug-related suppression of running activity. As discussed above, we propose that DR4004 and muscimol inhibit different components of the DRN pathway(s) that participate in phase resetting. Namely, DR4004 treatment inhibits the 5-HT 7 receptor-sensitive component of the DRN system for conveying behaviorally coded serotonergic input to the SCN. The muscimol treatment overrides an inhibitory influence of behavior over the GABA A receptor-mediated suppression of DRN serotonergic activity. The actions of both drugs inhibit DRN output to a similar extent, resulting in a suppressed behavioral phase-shifting response. It is notable that the intra-DRN drug treatments attenuated, but did not abolish, phase shifting, indicating that either DRN output was incompletely blocked by the drugs or that behavioral shifting can occur without DRN output. The latter possibility is supported by the finding that hamsters with 5-HT-specific neurotoxic lesioning of the DRN also can undergo novel wheelinduced phase advances (Meyer-Bernstein and Morin, 1998) . Interestingly, previous studies showing that electrical stimulation of the DRN at midday induces phase-advance shifts indicate that DRN output can evoke circadian phase resetting (Meyer-Bernstein and Glass et al., 2000) . Thus, serotonergic output from the DRN may be sufficient but not necessary for behavioral phase resetting, and its physiological role may be to augment the effects of other neuronal systems mediating clock resetting. The IGL is a good candidate in this regard because it receives serotonergic innervation from the DRN (Meyer-Bernstein and Morin, 1996) , and bilateral injection of 8-OH-DPAT in the IGL has a phase-advancing effect (Challet et al., 1998) [although unilateral IGL injection of 8-OH-DPAT is ineffective (Mintz et al., 1997) ]. Also, bilateral lesioning of the IGL blocks the phase-shifting effect of peripheral 8-OH-DPAT injection (Schuler et al., 1999) , and there is recent evidence that wheel-running at midday induces 5-HT release in the IGL region (J. D. Glass and G. H. Grossman, unpublished observations). The proposed mechanism by which behavioral information is encoded into serotonergic signaling relayed to the SCN (and possibly the IGL). This model is based on the present findings that (1) DRN-mediated SCN 5-HT release induced by electrical stimulation, GABA antagonist microinjection, or behavioral activation is blocked by intra-DRN or intra-MRN administration of 5-HT 7 receptor antagonists, indicating that the DRN communicates to the SCN via a 5-HT 7 -sensitive multisynaptic DRN3 MRN3 SCN pathway. DRN-stimulated SCN 5-HT release is blocked by intra-MRN injected 5-HT 7 antagonists, indicating that the MRN is a critical component of this pathway. (2) Intra-DRN or MRN injection of GABA A antagonist bicuculline stimulate SCN 5-HT release, indicating that raphe activity is tonically suppressed by GABA A receptor activation. (3) Intra-MRN injection of bicuculline and the GABA B antagonist 2-hydroxysaclofen (data not shown) equally stimulate SCN 5-HT release, indicating that MRN GABA B and GABA A receptors regulate SCN 5-HT release. (4) Electrical DRN stimulation induces 5-HT release in the MRN. This model proposes that behavioral activation suppresses the activity of GABA (1) neurons that tonically inhibit DRN 5-HT (1) neurons (and may also directly activate these 5-HT neurons). The 5-HT (1) neurons, when activated, inhibit DRN and MRN GABA (2 and 3) neurons that tonically suppress MRN 5-HT (2) neurons expressing both GABA A and GABA B receptors. Output from the stimulated 5-HT (1) neurons may also induce release of 5-HT in the IGL. The ensuing activation of the MRN 5-HT (2) neurons causes release of 5-HT from SCN terminals, according to the strength of the behavioral stimulus. This scheme does not rule out the possibility that behavior could also directly stimulate MRN activity. 5-HT 7 R, 5-HT 7 receptor; GABA A R, GABA A receptor; GABA B R, GABA B receptor; Ϫ, inhibition; ϩ, activation.
